Background. Accurate determination of kidney function is critical in the evaluation of living kidney donors and higher donor glomerular filtration rate (GFR) is associated with better allograft outcomes. However, among transplant centers donor kidney function evaluation varies widely. Methods. The performance of creatinine clearance (CrCl), Modification of Diet in Renal Disease (MDRD), the reexpressed MDRD equations with standardized creatinine, and the Cockcroft-Gault (CG) formula as compared with 125 I-iothalamate GFR (iGFR) was analyzed in 423 donors. All methods of GFR measurement were then evaluated for their association with graft function at 1 year. Results. The MDRD and re-expressed MDRD equations underestimated iGFR whereas CG showed minimal bias (median differenceϭϪ11.0, Ϫ16.3, and Ϫ0.5 mL/min/1.73 m 2 , respectively). CrCl overestimated iGFR (10 mL/min/ 1.73 m 2 ). The MDRD, re-expressed MDRD, and CG formulas were more accurate (88%, 86%, and 88% of estimates within 30% of iGFR, respectively) than CrCl (80% within 30% of iGFR). Interestingly, low bias and high accuracy were achieved by averaging the MDRD estimation with the CrCl result; both methods available to the clinician in most transplant centers. We also showed that predonation GFR as measured by isotopic renal clearance or any of the creatinine-based estimation formulas may be associated with allograft function at 1 year, whereas the widely used CrCl was not. Conclusions. Variable performance was seen among different GFR estimations, with CrCl being the poorest. Recent recommendations to use the MDRD equation with standardized serum creatinine did not improve its performance. However, recognizing the limited availability of GFR laboratories, these methods are still clinically useful if used with caution and understanding their limitations.
A ssessment of renal function is a critical component of donor evaluation. Ideally, measurement of glomerular filtration rate (GFR) requires a simple, reliable, accurate, and reproducible method. The sole use of serum creatinine (SCr) to estimate GFR in living donors is insufficient because its performance is quite variable when compared with more accurate methods such as isotope measurements of GFR. The use of a gold standard method such as the 125 I-iothalamate GFR (iGFR) is limited to select institutions because of its complexity and cost, rendering it unavailable to most transplant centers that evaluate live kidney donors. As such, clinicians must rely on surrogate markers of GFR as part of their donor evaluations. Currently, a wide array of approaches is used to assess kidney function in living kidney donors, with most centers using creatinine clearance (CrCl) or other forms of creatinine-based GFR estimations. It is widely accepted that a CrCl cutoff value of 80 mL/min is optimal for kidney donation; however, there are scarce data to support this recommendation (1) (2) (3) .
The performance of CrCl, and other creatininebased estimates of GFR compared with the gold standard GFR measurements by isotope clearance remains a matter of debate. Previous studies suggested that GFR cannot be estimated accurately and precisely using the current abbreviated Modification of Diet in Renal Disease (MDRD) Study (4) or Cockcroft-Gault (CG) (5) equations in potential kidney donors (3, 6 -10) . However, these studies did not include the widely used CrCl in their analyses nor the recently recommended re-expressed MDRD equation which employs a standardized SCr to improve the performance of the original MDRD formula (11) . Accurately estimating donor GFR is extremely important both to ensure a potential donor's medical suitability and to provide risk-stratification information that may help to predict future allograft performance because higher measured GFR of the donor is independently associated with improved allograft outcomes in living donor kidney transplantation (12, 13) .
Because different transplant centers use a wide range of approaches, how each available method of estimating GFR (in particular the widely used CrCl and the recently reexpressed MDRD equation) performs against a gold standard GFR method remains unclear. Additionally, recognizing that measured GFR by isotope clearance was previously shown to correlate well with recipient graft kidney function, we sought also to investigate if different GFR estimates can equally be associated with graft function. Thus, the purposes of this study were (1) to evaluate the performance of the CrCl and creatinine-based estimation equations including the newly re-expressed MDRD equation against iGFR measurements in a large cohort of living kidney donors, and (2) to evaluate whether these GFR estimations correlate equally with posttransplant graft function.
MATERIALS AND METHODS
A retrospective data base review was performed on 423 consecutive live adult kidney donors from 1996 to 2005 after approval by the Institutional Review Board at the Cleveland Clinic. Donor GFR had been measured using 125 I-iothalamate urinary clearances and adjusted to body surface area (BSA) as previously described (8) . The SCr and iGFR were assayed the same day, but at a variable time before donation. We evaluated the performance of estimated GFR (eGFR) by different methods: Recipients' GFR at 1 year posttransplant was estimated using the four-variable MDRD equation (14) . We had 422 recipients since two different live donors donated a kidney to a same recipient after first kidney transplant failed. We had 1-year posttransplant data on 399 of 422 recipients.
Iothalamate GFR was measured using the renal clearance of 125 I-iothalamate as described by Israelit et al. (15) . Patients received a water load before the test as follows: 1 to 2 L the previous night, at least 500 mL of water in the morning before the test, and approximately 10 mL/kg at the beginning of the test followed by as much water intake as possible during the test to keep the urine output between 200 and 400 mL/hr. Twenty-five mCuries of 125 I-sodium iothalamate (Glofil, Questor Pharmaceuticals, Inc., Union City, CA) were injected subcutaneously without epinephrine. Baseline urine and blood samples were obtained. A voluntary-voided urine sample was discarded, followed by two-timed clearance urine collections. Blood samples were drawn before and after each urine collection. Isotope activity was determined by gamma counting of 0.5 mL of plasma or urine on a Packard Minaxi 5000 series counter (Perkin Elmer Life Sciences, Downers Grove, IL). The counts in each period were the average of the bracketed samples for each clearance period. The mean GFR was calculated from two consecutive clearance values, and the results were then corrected to standard BSA (1.73 m 2 ) (16). This is almost the same procedure used in the MDRD and African American Study of Kidney Disease studies (17, 18) . The iGFR test variability at the Cleveland Clinic renal function laboratory is less than 10% if the test is repeated and the SCr level is not changed beyond its analytical variability.
Standardization of Serum Creatinine in Donors
Recently, Levey et al. (11) 
Creatinine Clearance
Special attention was taken to account for adequate 24-hr urine collection. A 24-hr urine collection was considered adequate if the 24-hr urine creatinine was 15 to 20 mg/kg for women or 20 to 25 mg/kg for men. Only one 24-hr urine collection was obtained per donor, because the reason for obtaining the 24-hr urine collection at Cleveland Clinic's transplant center was to rule out donor proteinuria and not to estimate kidney function. Among the 423 donors, 415 (98%) donors had a CrCl available; 263 of 415 (63%) donors had an adequate 24-hr CrCl, evidencing one of the major clinical limitations of this test.
Statistical Analysis
Precision was assessed by Pearson's correlation coefficient and Linn's concordance. Pearson's correlation coefficient measures the linear association between two measures. Linn's concordance is a measure of both the linear association between two measures, and the amount of deviation from the 45°line (line of equality). Bias, a measure of systematic error, was assessed by both median difference and median percent difference (eGFRϪiGFR), and accuracy was assessed as the percent of eGFR values falling within 10% and 30% of iGFR. The agreement of eGFR with iGFR was evaluated using residual plots, and Bland-Altman plots. Residual plots show the pattern of the error (difference between eGFR and iGFR) over the predicted value of GFR (eGFR). Loess was used in the residual plots to display the trend of the errors across the range of predicted values. Bland-Altman plots plot the difference between iGFR and eGFR by the average of the two measures. The overall mean is drawn with a solid line, and Ϯ2 SD is shown using dashed lines. These plots are also used to represent the trend of errors across the range of possible GFR values (20) .
Receiver-operating characteristic (ROC) curves were developed, and the area under the curve was used to assess whether each of the estimates of GFR (i.e., measured iGFR or eGFR by the various equations) predicted an eGFR more than 60 mL/min/1.73 m 2 at 1 year posttransplant. The best ROC cut-points were determined to maximize the sensitivity and specificity. We also compared the ability of each GFR estimate to predict graft function at 1 year in female versus male donors and African American versus non-African American donors using Hanley and McNeil's method of comparing independent ROC curves.
RESULTS

Donor and Recipient Characteristics
Baseline donor and recipient characteristics are presented in Table 1 . Donor mean age was 41 Ϯ9 years, 59% were women, and 82% were whites. The mean donor SCr was 0.8Ϯ0.2 mg/dL (range 0.4 -1.4), the mean donor adjusted iGFR was 106Ϯ17 mL/min/ Mean recipient age was 45Ϯ13 years, 42% were women and 83% were whites. Acute rejection (AR) was detected in 14% of the recipients, and as expected with live donor kidney transplantation, delayed graft function (DGF) was uncommon, occurring in only 7% of the cases. The recipients' mean eGFR by MDRD at 1 year posttransplantation was 55Ϯ18 mL/min/1.73 m 2 (range 5-110) and 38% of recipients had an eGFR more than 60 mL/min/1.73 m 2 at 1 year posttransplantation. The immunosuppressive regimen at 1 year posttransplant consisted of a calcineurin inhibitor-based regimen using cyclosporine or tacrolimus (nϭ251/399, 63%) or a calcineurin inhibitor-free regimen using sirolimus (nϭ148/399, 37%). All recipients received induction immunosuppression with an IL-2 receptor blocker or T cell-depleting antibodies and were on mycophenolic mofetil and glucocorticoids. Table 2 provides the overall precision, bias, and accuracy of estimation equations and CrCl with iGFR in this cohort of live kidney donors. All three formulas (MDRD, re-expressed MDRD, and adjusted CG equations) and CrCl (with adequate collection) demonstrated similar degrees of association with iGFR by Linn's concordance. Table 2 also shows the indices of bias (by both median difference and median percent difference) and accuracy (by percentage of estimates falling within 10% and 30% of iGFR) for all kidney function estimates. We also looked at the performance of the average between the MDRD estimate (as a measure of the lowest estimate available to the clinician because of the known underestimation of GFR) and CrCl (as a measure of the highest cutoff because of the known overestimation of GFR by this method).
Comparison of Estimated Glomerular Filtration Rate With Measured Glomerular Filtration Rate
Both the MDRD and the newly re-expressed MDRD equations underestimated iGFR (median percent differenceϭϪ10.9 mL/min/1.73 m 2 and Ϫ15.5 mL/min/1.73 m 2 , respectively) whereas the adjusted CrCl with adequate 24-hr urine collection overestimated iGFR (median percent differenceϩ9.9 mL/min/1.73 m 2 ). Little bias was observed with the adjusted CG equation or the average of MDRD and adjusted CrCl (median percent differenceϭϪ0.4 mL/min/1.73 m 2 and Ϫ1.4 mL/min/1.73 m 2 , respectively). The MDRD and CG equations had similar accuracy with 87.9% and 87.9% of estimates falling within 30% of iGFR respectively; only 79.9% of estimates by adjusted CrCl fell within 30% of iGFR. Interestingly, accuracy of the average of MDRD and adjusted CrCl showed 90% of estimates falling within 30%, and 49% of estimates falling within 10% of iGFR ( Table 2 ). The concordance coefficient was 0.39 and the bias was minimal. Figures  1 and 2 represent the graphical relationships between eGFR by all methods and iGFR using residual and Bland-Altman plots, respectively. The residual plots show that all of the eGFR methods tend to underestimate iGFR at lower values and overestimate iGFR at higher values.
We also asked the question of whether any of the methods performed better in African American versus white donors. There was a slight improved performance in bias (median difference) of the MDRD and re-expressed MDRD equations in African American donors than in whites, but not a significant one in the accuracy (data not shown).
Correlation of the Different Glomerular Filtration Rate Estimates With 1-Year Posttransplant Graft Function
As shown in Figure 3 and Table 3 , all measures were weakly predictive with posttransplant GFR more than 60 mL/ min at 1 year (PϽ0.001), except CrCl (though likely not clin- 
DISCUSSION
Accurate kidney function determination remains fundamental in the medical evaluation of potential live kidney donors. Customarily it is assessed by CrCl or estimated by different creatinine-based equations that were mainly derived from populations that differ in many respects to "healthy" donors (especially the MDRD formula). The results of our study add to the current medical knowledge in several ways. First, it is a comprehensive study of GFR assessment in one of the largest cohort of living kidney donors that not only includes the "traditional" GFR estimation equations, but also the widely used CrCl and the newly re-expressed MDRD equation. We showed that the newly recommended reexpressed MDRD equation did not improve the performance of the MDRD equation in this cohort of live kidney donors. Additionally, we have demonstrated that relying solely on CrCl for GFR determination in live kidney donors may be risky because of overestimation. Importantly, we found that a combination of easily obtainable methods (i.e., CrCl and MDRD equation) improves the estimation of GFR in our population, which may be clinically applicable to other centers that do not have easy access to measurement of GFR by the use of exogenous markers. Finally, a donor's GFR as assessed by CrCl did not correlate with posttransplant graft function, whereas other methods did to some degree.
In our study, the three creatinine-based estimation equations, that is, CG and both MDRD equations and the CrCl (with adequate urine collection) demonstrated similar concordance coefficients when compared with iGFR. However, the concordance coefficient is an index of precision and represents mainly the strength of the linear association between estimated and measured GFR, but it does not provide clinically applicable information on the overall performance of these equations. On the other hand, bias, a measure of systematic error, and agreement, as measured by accuracy, provides the clinician with better tools to assess the performance of estimation equations. The CG equation showed the lowest bias, whereas the CrCl overestimated iGFR and the MDRD formula tended to underestimate iGFR. However, slightly higher accuracy was noted with the MDRD equation. A plausible explanation of the interesting finding that the CG formula was almost unbiased in this cohort of live kidney donors is that the CG formula was derived from CrCl, which is known to overestimate iGFR (as a result of creatinine tubular secretion), and possibly the CG formula underestimates iGFR in health, analogously to the MDRD equation, thereby lowering the bias (8) . There are sparse data supporting a GFR cutoff value of 80 mL/min/1.73 m 2 as the lower limit for donation (1, 21, 22 ). Therefore, we should exercise caution when using the CrCl and the GFR estimation equations. As an example, when using CrCl the clinician can safely assume that the true GFR is likely to be lower than the obtained value. On the other hand, when using the MDRD equation the obtained GFR values may represent a low safe cutoff because of underestimation of GFR. Therefore, we queried what the performance of the combination of these estimates would be.
Intriguingly, low bias and the highest accuracy were observed when using the average of MDRD equation and CrCl. This low bias could be in part explained by the simple fortuitous cancellation of errors when combining a method that overestimates GFR (CrCl herein) with another method that underestimates GFR (MDRD herein), thus producing a mean value close to the mean iGFR. However, it is unclear 
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why the accuracy improves (important increase in eGFR values falling within not only 30% of iGFR but within 10% as well) because agreement should not simply improve by averaging the results. Nevertheless, the fact that the accuracy improves significantly with this maneuver is very important as the combination of these two readily available methods to estimate GFR could be clinically useful. The reason of the slight improvement of the bias of both the MDRD and reexpressed MDRD equations in African American donors versus white donors, that was not evident in the accuracy, may be explained by the fact that the MDRD equation underestimates iGFR in health and because the MDRD equation adjusts the calculated GFR by a factor of ϩ1.212 in African Americans, it thereby minimizes this underestimation. Therefore, we believe that this slight improvement in bias results from a "cancellation" of errors without significant improvement in the accuracy of the eGFR.
The information gathered from this study also shows that predonation GFR as measured by isotopic renal clearance or creatinine-based estimation formulas but not CrCl may allow for correlation with allograft function at 1 year after living kidney donation. The relatively poor performance of all methods, including the gold standard iGFR with areas under the ROC curves for all the estimates being approximately 0.6 (except the CrCl) may be explained by the fact that donor GFR is not the only independent factor that impacts posttransplant allograft function. Although we tried to account for some recipient factors such as AR and DGF, a multiplicity of other donor and recipient factors also play a role in posttransplant allograft function (12, 13) . These donor and recipient factors were well described in previous works; however, our main goal was not to confirm these findings but to analyze whether different GFR estimates were equally predictable of graft function analogously to measured isotopic GFR.
We acknowledge several limitations. This is a retrospective single center study. However, unlike any other published study, it includes quite a large cohort of multiethnic living kidney donors, implying that our results could likely be generalized to a larger pool of live donors in the United States. Moreover, previous similar reports did not include the widely available CrCl and the newly recommended re-expressed MDRD equation (6, 8) . Another limitation is that the donor evaluation at our institution includes only one 24-hr urine collection per donor and although unlikely, the use of twotimed urine collections might improve the performance of CrCl in assessing kidney function in living donors. Therefore, we opted to account for adequate 24-hr urine collection. We also recognize that calculated GFR by estimation equations to assess graft function has limitations. Additionally one could argue that it is not surprising that the MDRD equation best predicted graft function at 1 year, as the latter was also measured by the MDRD equation. However, the MDRD equation that we used herein has performed better than other formulas in renal transplantation in our own experience (10, 14) . We did not use the re-expressed MDRD equation to estimate recipients' GFR because it has not been validated in kidney transplant recipients, and based on our experience showed no improvement.
In conclusion, none of the assessed methods including CrCl and the newly recommended MDRD equation provided statistically highly reliable information about GFR estimation. Nevertheless, the overall performance of the MDRD and CG equations against isotope GFR measurement is superior to the CrCl in this cohort of live kidney donors. These data also suggest that the recent refinements of the MDRD formula to increase its reliability did not improve the performance of the original formula in our cohort of healthy kidney donors. However, in the absence of better alternatives, these methods may still be clinically useful in the context of individual donor evaluation if used with caution and clear understanding of their limitations. 
